| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $233.7K | 0.00% | 47.89K | −64% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a PASG trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jun 24, 2026 | Lynx1 Capital Management LpBeneficial Owner of more than 10% of a Class of Security | Purchase at price 4.12 per share. | 50.1K | $206.10K |
| Jan 7, 2026 | Chou WilliamChief Executive Officer | Sale at price 18.44 per share. | 4.1K | $75.16K |
| Jan 7, 2026 | Borthwick KathleenChief Financial Officer | Sale at price 18.44 per share. | 2.1K | $38.02K |
| Jan 7, 2026 | Chou WilliamChief Executive Officer | — | 10K | — |
| Jan 7, 2026 | Borthwick KathleenChief Financial Officer | — | 5K | — |
| Sep 14, 2025 | Lynx1 Capital Management LpBeneficial Owner of more than 10% of a Class of Security | Purchase at price 6.96 - 6.99 per share. | 32K | $223.74K |
| Jul 23, 2025 | Lynx1 Capital Management LpBeneficial Owner of more than 10% of a Class of Security | Purchase at price 5.44 - 5.74 per share. | 128.8K | $733.83K |
| Jun 25, 2025 | Orbimed Advisors, L.L.C.Beneficial Owner of more than 10% of a Class of Security | Sale at price 0.33 - 0.35 per share. | 583.7K | $197.24K |
| Apr 23, 2025 | Orbimed Advisors, L.L.C.Beneficial Owner of more than 10% of a Class of Security | Sale at price 0.32 - 0.34 per share. | 235.6K | $78.73K |
| Apr 16, 2025 | Orbimed Advisors, L.L.C.Beneficial Owner of more than 10% of a Class of Security | Sale at price 0.33 - 0.38 per share. | 149.1K | $49.70K |
| Feb 10, 2025 | Borthwick KathleenChief Financial Officer | Sale at price 0.53 per share. | 3.2K | $1.69K |
| Feb 9, 2025 | Borthwick KathleenChief Financial Officer | — | 8K | — |
| Jan 13, 2025 | Orbimed Advisors, L.L.C.Beneficial Owner of more than 10% of a Class of Security | Sale at price 0.60 - 0.66 per share. | 223.2K | $142.22K |
| Jan 7, 2025 | Orbimed Advisors, L.L.C.Beneficial Owner of more than 10% of a Class of Security | Sale at price 0.68 - 0.77 per share. | 147K | $103.31K |
| Dec 26, 2024 | Lynx1 Capital Management LpBeneficial Owner of more than 10% of a Class of Security | Purchase at price 0.65 per share. | 373.6K | $241.04K |
| Dec 19, 2024 | Orbimed Advisors, L.L.C.Beneficial Owner of more than 10% of a Class of Security | Sale at price 0.60 per share. | 230.3K | $138.19K |
| Dec 10, 2024 | Orbimed Advisors, L.L.C.Beneficial Owner of more than 10% of a Class of Security | Sale at price 0.80 - 0.84 per share. | 62.3K | $51.99K |
| Dec 5, 2024 | Orbimed Advisors, L.L.C.Beneficial Owner of more than 10% of a Class of Security | Sale at price 0.79 - 0.82 per share. | 97.1K | $77.34K |
| Nov 26, 2024 | Lynx1 Capital Management LpBeneficial Owner of more than 10% of a Class of Security | Purchase at price 0.56 - 0.71 per share. | 456.4K | $284.52K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -2.5 | -20.7 | -13.9 | -34.9 | 12.9 | -15.4 | -8.4 | -0.9 | 1.6 | -19.1 | −69.2% | ||
| 2025 | 3.0 | -11.3 | -31.9 | -7.6 | 33.7 | -8.3 | -19.7 | 11.1 | 12.6 | -4.4 | 15.0 | 33.6 | +4.1% |
| 2024 | -3.0 | 74.5 | -21.1 | -4.4 | -11.6 | -30.4 | 12.1 | -21.2 | -0.1 | -12.1 | 83.7 | -49.8 | −43.9% |
| 2023 | 5.8 | -15.8 | -22.1 | 8.6 | -8.6 | -1.1 | -6.4 | -11.4 | -15.7 | -2.7 | -1.4 | 60.1 | −26.8% |
| 2022 | -20.8 | -34.0 | -6.6 | -37.1 | -7.7 | 31.1 | -20.8 | 8.0 | -38.1 | -2.4 | 0.0 | 13.1 | −78.3% |
| 2021 | -27.0 | -3.4 | -3.0 | 7.3 | -29.4 | -0.1 | -10.9 | 1.9 | -17.1 | -12.4 | -16.4 | -12.9 | −75.2% |
| 2020 | -29.1 | 5.1 | 33.1 | 24.1 | -42.8 | 5.9 | -20.8 | 28.2 | 22.0 | 24.7 | +15.2% |
Buy / hold / sell counts
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other programs for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is based in Philadelphia, Pennsylvania.
No recent headlines.